It is very likely that blocking NF-κB activation might enhance tumor cell sensitivity to TRAIL-induced apoptosis [56] and inhibit inflammation-mediated tumor promotion in the tumor microenvironment, thus enhancing TNFα function in sensitization of metastatic colon carcinoma cells in TRAIL therapy, which requires further study. This evidence concerns the gene NFKB1 and neoplasm.